Moderna Inc’s ‘MRNA.O’ experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial, the company said on Monday. “We are going to have a vaccine that can stop COVID-19,” Moderna President Stephen Hoge said in a telephone interview.
With this, Moderna became the second U.S. drug-maker to report results that have far exceeded expectations after Pfizer Inc’s ‘PFE.N’ vaccine, which is also more than 90% effective, and pending more safety data and regulatory review. Moderna expects to have enough safety data required for U.S. authorization in the next week or so and expects to file for emergency use authorization (EUA) in the coming weeks.
The United States could have two vaccines authorized for emergency use in December with as many as 60 million doses of vaccine available this year. However, unlike Pfizer’s vaccine, Moderna’s shot can be stored at normal fridge temperatures, which will make it easier for distribution.